Transchem
154.65
-8.00(-4.92%)
Market Cap₹189.31 Cr
PE Ratio67.77
IndustryHealthcare
Company Performance:
1D-4.92%
1M-16.25%
6M+153.52%
1Y+336.49%
5Y+804.39%
View Company Insightsright
More news about Transchem
07Aug 25
Transchem Limited Reports 40% Drop in Q1 Net Profit Amid Revenue Decline
Transchem Limited (BSE: 500422) reported a significant decline in financial performance for Q1 2025. Total income decreased by 33.77% to ₹163.58 lakhs, while net profit fell by 40.24% to ₹99.33 lakhs compared to Q1 2024. The company reported no revenue from operations, with income solely from other sources. Despite the revenue decline, total expenses remained relatively stable at ₹28.48 lakhs. Basic EPS decreased to ₹0.81 from ₹1.36 in the previous year. The company's paid-up equity share capital stands at ₹1,224 lakhs, with other equity at ₹6,707.54 lakhs as of March 31.
 no imag found
Transchem
154.65
-8.00
(-4.92%)
1 Year Returns:+336.49%
Industry Peers
Sun Pharmaceutical
1,728.50
(-1.63%)
Divis Laboratories
5,906.50
(-0.68%)
Torrent Pharmaceuticals
4,111.30
(-2.58%)
Lupin
2,274.90
(-1.69%)
Dr Reddys Laboratories
1,209.60
(-3.61%)
Cipla
1,195.90
(-2.31%)
Zydus Life Science
863.20
(-0.92%)
Mankind Pharma
2,001.30
(-0.22%)
Aurobindo Pharma
1,342.10
(+2.89%)
Alkem Laboratories
5,244.50
(-1.03%)